Recent News

• 10.26.2026 - Hepion Pharmaceuticals Receives FDA Feedback Supporting a Path to Demonstrating Prophylactic Protection for GV104 Against Fentanyl-Induced Cardiac Arrest
• 10.19.2026 - Hepion Pharmaceuticals Receives Positive FDA Response on GV104 in Gambling Disorder, a Condition With No Approved Medication
• 10.14.2026 - Hepion Pharmaceuticals Completes Acquisition of Gravitas Life Sciences and Provides Corporate Update
• 03.03.2026 - Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma
• 06.25.2025 - Hepion Pharmaceuticals Successfully Completes Application to the OTCQB
• 06.16.2025 - Hepion Pharmaceuticals Announces Dr. Kaouthar Lbiati as Interim Chief Executive Officer
• 05.12.2025 - Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq
• 03.14.2025 - Hepion Pharmaceuticals Announces Reverse Stock Split
• 01.22.2025 - Hepion Pharmaceuticals Announces $9.0 Million Public Offering
• 12.11.2024 - Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd.

Recent Filings

• 10.27.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.27.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.27.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.27.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.27.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.27.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.27.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.27.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.26.2026 - SCHEDULE 13D General Statement of Acquisition of Beneficial Ownership
• 10.21.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors